Amalgamated Bank’s UroGen Pharma URGN Stock Holding History

Amalgamated Bank’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,159	Closed	-$27K	–	2758
2025 Q4	$27K	Sell	1,159 -176	-13%	-$3.82K	﹤0.01%	2004
2025 Q3	$27K	Hold	1,335	–	–	﹤0.01%	2016
2025 Q2	$18K	Hold	1,335	–	–	﹤0.01%	2163
2025 Q1	$15K	Buy	1,335 +392	+42%	+$4.18K	﹤0.01%	2192
2024 Q4	$10K	Hold	943	–	–	﹤0.01%	2451
2024 Q3	$12K	Hold	943	–	–	﹤0.01%	2379
2024 Q2	$16K	Hold	943	–	–	﹤0.01%	2221
2024 Q1	$14K	Sell	943 -2,295	-71%	-$37.5K	﹤0.01%	2301
2023 Q4	$49K	Buy	3,238 +466	+17%	+$6.05K	﹤0.01%	2261
2023 Q3	$39K	Hold	2,772	–	–	﹤0.01%	2360
2023 Q2	$29K	Buy	+2,772	New	+$30.6K	﹤0.01%	2555
2022 Q2	–	Sell	-2,960	Closed	-$26K	–	3205
2022 Q1	$26K	Buy	+2,960	New	+$23.1K	﹤0.01%	2725

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Amalgamated Bank's URGN Position: Q1 2026 in Review

Amalgamated Bank sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 1,159 shares — an estimated $27K sold.

Amalgamated Bank first reported a position in URGN in Q1 2022 and held it in 12 quarters. The position peaked at $49K in Q4 2023. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

Amalgamated Bank reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
Amalgamated Bank sold 1,159 UroGen Pharma shares in Q1 2026, an estimated $27K.
Amalgamated Bank first reported a position in UroGen Pharma in Q1 2022 and held it in 12 quarters.
Amalgamated Bank's UroGen Pharma position peaked at $49K in Q4 2023.
173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.